The emergence of antimalarial drug resistance poses a major threat to effective malaria treatment and control in sub-Saharan Africa. The RTS, S/AS01 vaccine has the potential to reduce both resistant infections and antimalarial use. Modeling studies projecting aggregate health burden averted under different scenarios can support further vaccine development and implementation. OHT researchers created a mathematical model that can project cases, drug-resistant infections, and deaths averted from 2021 to 2030 with a vaccine against clinical malaria.
Bill & Melinda Gates Foundation
- Hamilton, A., Haghpanah, F., Hasso-Agopsowicz, M., Frost, I., Lin, G., Schueller, E., Klein, E., & Laxminarayan, R. (2022). Malaria Vaccine Impact on Cases, Drug-resistant Cases, and Deaths in Africa: A Modeling Study. Research Square. Available here.
- Hamilton, A., Haghpanah, F., Hasso-Agopsowicz, M., Frost, I., Lin, G., Schueller, E., Klein, E., & Laxminarayan, R. (2023). Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries. Communications Medicine (an open access journal from Nature Portfolio). Available here.